Researcher Hojun Li and his team have developed a new Covid-19 at-home test that looks “specifically at the levels of neutralizing antibodies and either give a precise level or a ‘low,’ ‘medium,’ ‘high’ reading, providing more actionable information,” reports Karen Weintraub for USA Today.
Reuters reporter Nancy Lapid writes that MIT researchers have developed an at-home test that can measure a person’s antibody levels to the virus that causes Covid-19. The test could someday “help people know how protected they are against infection and what kinds of precautions they need to take,” writes Lapid.
Daily Beast reporter Tony Ho Tran writes that a new paper test developed by MIT researchers could be used to help determine a person’s immune response to Covid-19. “The researchers believe that the new test can not only help folks find out if they should get boosted,” writes Tran, “but also help the most vulnerable populations make sure they’re protected against the coronavirus, and help people make more informed decisions on what kinds of activities they should feel safe doing.”
Boston.com reporter Madeleine Aitken writes that MIT researchers have created a new blood test that can measure immune protection against Covid-19. The new test measures the “level of neutralizing antibodies in a blood sample, using the same type of ‘lateral flow’ technology as antigen tests,” writes Aitken.
Boston Herald reporter Rick Sobey writes that MIT researchers have developed a blood test that can predict Covid-19 immunity. “The MIT researchers created a paper test that measures the level of neutralizing antibodies in a blood sample, which could help people decide what protections they should take against infection,” writes Sobey. “Their test uses the same type of 'lateral flow' technology as most rapid antigen tests for Covid.”
Forbes contributor Russell Flannery spotlights how Prof. Tyler Jacks has “made a mark in cancer work not only by his research but his ability to bring different organizations together.” Jacks discussed the Biden administration’s “Cancer Moonshot” initiative and noted that: “Having specific goals and an action plan for cancer is important. Having a strategy about how to approach the cancer problem is equally important.”
Scientists at MIT are developing a self-boosting vaccine that can provide multiple doses of a vaccine via a single injection, reports Darko Manevski for Newsweek. The technology “could be particularly useful for administering childhood vaccinations in regions where people do not have regular access to medical care,” writes Manevski.
MIT scientists are developing self-boosting vaccine technology that could allow people to receive all of their vaccine doses in one shot, reports The Economist. This technology “would be a game-changer, not only for future pandemics but also for vaccination programs in remote regions where it is harder to deliver boosters,” The Economist notes.
The Boston Globe highlights Robert Buderi’s new book, “Where Futures Converge: Kendall Square and the Making of a Global Innovation Hub.” Buderi features the Future Founders Initiative, an effort by Prof. Sangeeta Bhatia, President Emerita Susan Hockfield and Prof. Emerita Nancy Hopkins aimed at increasing female entrepreneurship.
STAT has named Noubar Afeyan ’87, Cornelia Bargmann PhD ’87, Prof. Regina Barzilay and Prof. Sangeeta N. Bhatia to their list of trailblazing researchers working in the life sciences. “Many of the STATUS List are well-known as change makers; others are largely unheralded heroes. But all have compelling stories to tell,” writes STAT.
David Lucchino ’06 and Prof. Robert Langer have co-founded Frequency Therapeutics, a biotechnology company focused on developing a new approach to restoring hearing from the most common form of hearing loss, reports Jack Kelly for Forbes. “FX-322 is designed to treat the underlying cause of SNHL (sensorineural hearing loss) by regenerating sensory hair cells through activation of progenitor cells already present in the cochlea,” writes Kelly.
Researchers from MIT and the La Jolla Institute for Immunology have found a vaccine ingredient that may strengthen immune response, reports Natalie Colarossi for Newsweek. This combination-style vaccine ingredient “may boost the effectiveness of inoculations ranging from HIV to Covid-19,” writes Colarossi.
Forbes reporter Jack Kelly profiles Institute Prof. Robert Langer, spotlighting his career journey and his passion for helping others. “I traded job security and high pay for doing things I was passionate about,” Langer explains. “Out of over 20 job offers I received upon graduation from college, I chose the lowest paying one by far because I thought by doing so, I could potentially improve the health of patients. I dreamed about doing things that I thought would make the world a better place.”
Writing for the NIH Director’s Blog, Dr. Francis Collins highlights how Prof. Tyler Jacks and research scientist Megan Burger’s work exploring T cell exhaustion led to the creation of a “strategy for developing cancer vaccines that can ‘awaken’ T cells and reinvigorate the body’s natural cancer-fighting abilities.” Collins writes that “the researchers hope to learn if this approach to cancer vaccines might work even better when used in combination with immunotherapy drugs, which unleash the immune system against cancer in other ways.”
Boston Globe reporter Steve Annear spotlights research specialist Kathy Cormier’s dedication to tending a flower planter at the Collier Memorial. “Here’s something that’s empty that I can fill, and make myself feel better and make other people — hopefully — feel better,” says Cormier. MIT Chief of Police John DiFava says, “what she is doing is just so amazing. I just think it’s wonderful and it’s so illustrative of the way we have been treated here.”